Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022 report gives
comprehensive insight on clinical and non-clinical developments in the field of cancer
immunotherapy. According to report, cancer immunotherapy has emerged as the new growth
frontier for the pharmaceutical companies involved in the clinical research and development
of cancer drugs and therapeutics. Currently there are more than 2000 cancer
immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in
preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal
antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially
available in the market.
Cancer immunotherapeutics based on these discoveries would pave path for market
introduction of highly effective therapeutics. Some progress has been made which could be
noticed by observing plethora of cancer immunotherapeutics available for different cancer
indications. Their clinical pipeline is also developing rapidly and various products are at
different stages of clinical trials. They are expected to offer severe competition to presently
available cancer therapeutics with modest pharmacological efficacy.
Cancer immunotherapies have been used for limited number of malignancies as compared to
other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic
lymphocytic leukemia and diffuse large B cell non-Hodgkins lymphoma have remained the
focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have
also got cancer immunotherapeutics.
Most like, cancer therapeutics in clinical trials would be able to present positive data that
will allow them to easily enter in global market. Cancer incidences are escalating rapidly and
cancer immuno therapeutics seems to play an important role in offering better medical care
to patients. Some of them have received FDAs accelerated approval and breakthrough
therapy designation due to their superior pharmacological benefits. It is expected that similar
progress would be shown by cancer immunotherapeutics under development for different
malignancies.
Table of Contents
19.1 Bevacizumab
19.5 Catumaxomab
19.6 Ipilimumab
19.7 Nivolumab
19.8 Pembrolizumab
19.9 Pertuzumab
19.10 Rituximab
19.11 Trastuzumab
21.1 Abbvie
21.2 Advaxis
21.4 Amgen
21.6 Biogenomics
21.12 Genmab
21.14 GlaxoSmithKline
21.16 ImmunoGen
21.19 Merck
21.23 Novartis
21.25 Pfizer
21.26 Philogen
21.27 Regulon
21.28 Roche
21.30 ZymoGenetics
List of Figures
Figure 14-13: Global - Cancer Immunomodulators Clinical Pipeline By Phase (Number), 2017 -
2022
Figure 15-1: Favorable Cancer Immunotherapy Market Parameters
Figure 15-2: Cancer Immunotherapy Commercialization Challenges
Figure 21-1: Advaxis Clinical Pipeline
Figure 21-2: Celldex Therapeutics Clinical Pipeline
Figure 21-3: Expression Genetics Clinical Pipeline
Figure 21-4: Galena Biopharma Clinical Pipeline
Figure 21-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 21-6: ImmunoGen Clinical Pipeline
Figure 21-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 21-8: NewLink Genetics Corporation Clinical Pipeline
Figure 21-9: Northwest Biotherapeutics Clinical Pipeline
Figure 21-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 21-11: Philogen Clinical Pipeline
Figure 21-12: Seattle Genetics Clinical Pipeline